AIM AT MELANOMA

Continued line 4a from schedule onurse/physician education initiativein october 2016 aim created the melanoma nursing initiative (mni). The recent expansion of melanoma therapy has increased the complexity of disease management. Patients with melanoma may discontinue therapy if not adequately engaged in their own care or supported when they experience side effects. As well, more patients are being treated in the community setting, where expertise is frequently lacking to address these challenges. The mni consists of:1. Melanoma nurse resource center portal (themelanomanurse.org)this portal provides a 1-stop shop for all the educational materials developedcontent includes consensus statements, side-effect search functions, cme activities, a supportive care q/a portal, and a patient resource center.2. Melanoma nurse management toolkithelpful resources such as algorithms, checklists, printable sheets, and searchable content on supportive care aspects of melanoma therapy (side effect management as well as adherence issues), key resources on targeted therapy, immunotherapy, and intralesional immunotherapy online resources as well as print pieces for distribution at regional cancer meeting.3. Cjon (ons) supplement on optimizing outcomes for melanoma therapies 7-article supplement in cjon to include an introduction by 2 melanoma physicians, an overview document from our chair, and 5 articles on support strategies for targeted therapy, immunotherapy, and intralesional immunotherapy articles are made available through open access located on our portal.4. Jadpro supplement on the management of immune related adverse events this 4-article supplement in jadpro covers immuno-oncology therapy essentials: proactive management of immune-related adverse events. Both the cjon and jadpro supplements are available as well on the mni website.5. Jco oncology practice on interdisciplinary care for management of complex iraes. The articles in the supplement covers immuno-oncology applications in clinical scenariosintroduction, toxicity management of front-line pembrolizumab combined with axitinib in clear cell metastatic renal cell carcinoma: a case study approach, management of pneumonitis and neuropathy in patients receiving pd-1based therapy for nonsmall-cell lung cancer, the management of immune-related dermatitis and mucositis associated with pembrolizumab in metastatic human papillomavirusassociated squamous cell carcinoma of the oropharynx, and atypical presentations and management of endocrine and hepatic immune-related adverse events from adjuvant immune checkpoint inhibitor therapy in stage iii resected melanoma. The jco supplement are available as well on the mni website.6. Aim continued to provide an interactive, web based education on braf/mek inhibitor therapy for melanoma to improve the outcomes through indisciplinary care. 7. Development of patient resource materials customized patient resource/education materials (printable pdfs) have been developed that can be downloadable from the website and distributed by nurses/physician assistants and other hcps. Topics include the goals of therapy, the side effects of therapies, important points/strategies around adherence, as well as other supportive resources, such as call-in numbers for financial or other assistance, etc. Specific content on targeted therapies, immunotherapies, combinations, intralesional immunotherapies, and the adjuvant setting are included.8. Development of patient and hcp videos have been developed to address the issues of prevention and early detection, surgery, pathology, treatment, side effects and managmenet for both targeted and immunotherapies, clinical trials, and living with melanoma. The hcp videos were developed to assist hcps to care for patients during covid. The videos are available on aim at melanoma site's youtube channel.9. Aim provided web based education on strategies to support shared decision making in the stage ii setting. The education is available as well on the mni website.